Dr. Reddys Laboratories Stock prices added percent in the morning session on June 28 after the company launched 2-deoxy-d-glucose (2-DG), the therapeutic application for the treatment of Covid-19 patients.
Stock traded at Rs 5,352.10, up RS 40.75, or 0.77 percent at 09:44 hours. It has touched the highest intraday RS 5,381.85 and Low intraday Rs 5,312.65.
Labor Laboratory Reddy announced a 2-deoxy-d-glucose commercial launch (2-DG). The company will supply to the main government and private hospitals throughout India. In the early weeks, the company would make drugs available in hospitals in Metros and Tier 1, and then expand coverage throughout India, the company said in the exchange of exchanges.
Catch all market actions on our direct blog
“2-DG produced by Dr. Reddy has 99.5 percent purity and is being commercially sold with the 2DG ™ brand. The maximum retail price of each sachet has been repaired in the RS. 990, with the level of subsidies offered to Government Institutions.,” Company add.
Dr. Reddy’s, on June 22, said that it had launched a generic version of Vascepa in the US. Vascepa is used in caring for patients with high triglyceride levels.
The launch came a day after the US Supreme Court refused an offer by Amarin Corporation to revive six patents Vascape. In 2020, the Federal Circuit Court decided to support Dr. Reddy and other generic drug makers who had challenged Amarin’s patent claims for the drug.
